Castration-Resistant Prostate Cancer (CRPC)
What is Castration-Resistant Prostate Cancer (CRPC)?
Castration-resistant prostate cancer, or CRPC, is a form of prostate cancer that continues to grow even when testosterone levels are very low. Testosterone is a male hormone that typically fuels prostate cancer growth. Most men with advanced prostate cancer receive hormone therapy, also called androgen deprivation therapy, to lower testosterone levels.
CRPC develops when cancer cells learn to grow without needing normal amounts of testosterone. The cancer adapts and finds new ways to survive despite castrate testosterone levels below 50 nanograms per deciliter. This resistance usually happens after months or years of successful hormone therapy.
Rising PSA, or prostate-specific antigen, is the earliest sign that cancer has become resistant to treatment. PSA is a protein made by prostate cells that increases when cancer cells multiply. Monitoring PSA levels helps doctors detect resistance early and adjust treatment plans before cancer spreads further.
Symptoms
- Rising PSA levels despite ongoing hormone therapy
- Bone pain, especially in the spine, hips, or ribs
- Increased fatigue and weakness
- Difficulty urinating or weak urine flow
- Blood in urine or semen
- Unexplained weight loss
- Swelling in legs or pelvic area
- Numbness or weakness in legs or feet
Some men with early CRPC have no symptoms except rising PSA. Cancer may be active at the cellular level before causing physical symptoms. Regular PSA monitoring catches progression early when treatment options are more effective.
Concerned about Castration-Resistant Prostate Cancer (CRPC)? Check your levels.
Screen for 1,200+ health conditions
Causes and risk factors
CRPC develops when prostate cancer cells mutate and adapt to survive without testosterone. Cancer cells may increase androgen receptors, produce their own androgens, or activate growth pathways that bypass the need for hormones. These genetic changes allow tumors to resist androgen deprivation therapy that previously controlled the disease. Duration of hormone therapy and cancer biology influence when resistance develops.
Risk factors include longer time on hormone therapy, higher initial PSA levels, and aggressive cancer characteristics at diagnosis. Age, family history of prostate cancer, and African ancestry increase overall prostate cancer risk. Men with metastatic disease that has spread to bones or other organs face higher risk of developing treatment resistance over time.
How it's diagnosed
CRPC is diagnosed through PSA monitoring during hormone therapy. Doctors look for three consecutive PSA rises, with two increases more than 50% above the lowest point reached during treatment. Testosterone levels must remain in the castrate range below 50 nanograms per deciliter. This pattern confirms that cancer is growing despite continued hormone suppression.
Rite Aid offers PSA testing through Quest Diagnostics at over 2,000 locations nationwide. Regular PSA monitoring helps detect treatment resistance early. Imaging tests like bone scans or CT scans may be ordered to check if cancer has spread. Biopsies are sometimes performed to understand the cancer's current characteristics and guide treatment decisions.
Treatment options
- Next-generation hormone therapies like abiraterone or enzalutamide that block androgen production more completely
- Chemotherapy with docetaxel or cabazitaxel for more advanced disease
- Targeted radiation to bone metastases causing pain
- Radium-223 therapy for cancer that has spread to bones
- PARP inhibitors for men with specific genetic mutations
- Immunotherapy for tumors with certain biomarkers
- Clinical trials testing new targeted therapies
- Bone-strengthening medications to prevent fractures
- Pain management and supportive care
- Anti-inflammatory diet focused on vegetables, omega-3 fatty acids, and limited processed foods
- Regular exercise to maintain muscle mass and bone strength
- Stress reduction through mindfulness or support groups
Need testing for Castration-Resistant Prostate Cancer (CRPC)? Add it to your panel.
- Simple blood draw at your nearest lab
- Results in days, not weeks
- Share results with your doctor
Frequently asked questions
Castration-resistant means the cancer continues growing even when testosterone is lowered to castrate levels below 50 nanograms per deciliter. Most prostate cancers initially respond to hormone therapy that reduces testosterone. Over time, cancer cells adapt and find ways to grow without needing normal testosterone levels. This resistance typically develops after months or years of successful hormone treatment.
CRPC is a more advanced stage that develops after hormone therapy stops working effectively. Regular prostate cancer depends on testosterone to grow and responds well to hormone-blocking treatments. CRPC has evolved to survive despite very low testosterone levels. It requires more intensive treatments like next-generation hormone therapies, chemotherapy, or targeted drugs.
CRPC is diagnosed by PSA trends rather than a single number. Doctors look for three consecutive PSA rises with at least two increases more than 50% above the lowest point during treatment. The actual PSA value varies by person. Rising PSA despite castrate testosterone levels below 50 nanograms per deciliter confirms treatment resistance.
Most doctors recommend PSA testing every 3 to 6 months during hormone therapy. More frequent testing every 1 to 3 months may be needed if PSA starts rising. Regular monitoring catches treatment resistance early when intervention is most effective. Your oncologist will determine the best testing schedule based on your cancer characteristics and treatment response.
Lifestyle changes support medical treatment but cannot cure CRPC alone. An anti-inflammatory diet rich in vegetables, healthy fats, and limited processed foods may help slow progression. Regular exercise maintains muscle mass, bone strength, and quality of life during treatment. Stress management through support groups or mindfulness can improve mental health. Always combine lifestyle changes with medical care from an oncologist.
Rising PSA signals that current treatment is no longer controlling cancer growth. Your oncologist will likely switch to a different therapy based on your treatment history and cancer characteristics. Options include next-generation hormone drugs, chemotherapy, targeted therapies, or clinical trials. Imaging tests may be ordered to check if cancer has spread to new areas requiring additional treatment.
CRPC is generally not curable but is often treatable for months or years. Multiple treatment options can control cancer growth, relieve symptoms, and extend survival. Many men live well with CRPC through sequential therapies as each treatment eventually stops working. Research continues developing new drugs that target specific cancer vulnerabilities and improve outcomes.
Next-generation hormone therapies block testosterone production or action more completely than older treatments. Abiraterone stops androgen production in the adrenal glands and tumor itself. Enzalutamide blocks androgen receptors on cancer cells more powerfully. These drugs often control PSA and slow progression for many months before resistance develops again.
Not all CRPC spreads to bones, but bone metastases are common in advanced cases. Prostate cancer has a tendency to spread to the spine, hips, ribs, and pelvis. Bone involvement causes pain and increases fracture risk. Bone scans or PET scans detect metastases early so protective treatments can begin promptly.
See your oncologist immediately if you develop new bone pain, difficulty walking, numbness in legs, or severe fatigue. These symptoms may indicate cancer progression requiring treatment adjustment. Keep all scheduled appointments for PSA monitoring and imaging even without symptoms. Rising PSA often precedes physical symptoms by weeks or months, allowing earlier intervention.